LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
== Therapeutic use == Recent studies have shown that SK channels do not only regulate afterhyperpolarization, they also have an effect on synaptic plasticity. This is the activity-dependent adaptation of the strength of synaptic transmission. Synaptic plasticity is an important mechanism underlying learning and memory processes. Apamin is expected to influence these processes by inhibiting SK channels. It has been shown that apamin enhances learning and memory in rats and mice. This may provide a basis for the use of apamin as a treatment for memory disorders and cognitive dysfunction. However, due to the risk of toxic effects, the therapeutic window is very narrow. SK channel blockers may have a therapeutic effect on Parkinson's disease. Dopamine, which is depleted in this disease, will be released from midbrain dopaminergic neurons when these SK channels are inhibited. SK channels have also been proposed as targets for the treatment of epilepsy, emotional disorders and schizophrenia.
Human Growth Hormone Fragment 176–191 (hGH frag 176–191) is a peptide fragment of human growth hormone. It has erroneously been presented as a lipolytic peptide fragment based on extrapolations of clinical data pertaining to AOD9604, a modified form of hGH frag 176–191. In contrast to AOD9604, hGH frag 176–191 has not been studied in humans.
12 September 1946 the minister for external affairs in India, Jawaharlal Nehru demanded in a letter to the Commander in Chief and Defence Secretary, that a large-scale reform should be implemented to improve the Indian Army. Calcutta had been ravaged by large communal riots, but the British Indian Army was able to restore order. Nehru demanded with urgency, that the Indian Army should safeguard India's new democracy. Nehru was a nationalist and opposed India's "divide and rule" policy.
== Physical appearance == Wild type fruit flies are yellow-brown, with brick-red eyes and transverse black rings across the abdomen. The fly's body is divided into three main parts: head, thorax, and abdomen. The head is relatively round and features large, prominent red compound eyes. These eyes are made up of hundreds of ommatidia and occupy most of the head's surface. The brick-red color of the eyes of the wild type fly are due to two pigments: xanthommatin, which is brown and is derived from tryptophan, and drosopterins, which are red and are derived from guanosine triphosphate. Between the eyes are short antennae, which look like tiny feathery or bristled projections and are used for detecting odors, air currents, and vibrations. Drosophila also has bristles—short, stiff hairs—distributed across the head and body, which are useful for tactile sensing.
Sources: en.wikipedia.org
=== Committee assignments === As an independent, Sanders maintains an agreement with the Senate Democratic leadership where he votes with the Democrats on all procedural matters unless the Democratic whip, Dick Durbin, agrees that he need not (a request rarely made or granted). In return he was allowed to keep his seniority and received the committee seats that would have been available to him as a Democrat; in 2013–14 he was chairman of the United States Senate Committee on Veterans' Affairs (during the Veterans Health Administration scandal). Sanders became the ranking minority member on the Senate Budget Committee in 2015 and the chair in 2021; he previously chaired the Senate Veterans' Affairs Committee for two years. Since 2017, he has been chair of the Senate Democratic Outreach Committee. He appointed economics professor Stephanie Kelton, a modern monetary theory scholar, as the chief economic adviser for the committee's Democratic minority and presented a report about helping "rebuild the disappearing middle class" that included proposals to raise the minimum wage, boost infrastructure spending, and increase Social Security payments.
The 12th congressional district shifted significantly in the 2020 United States redistricting cycle following the 2020 census: while it kept Dearborn, it lost Ann Arbor while gaining parts of Detroit. While prior to redistricting, Dingell lived in Dearborn, she chose to move to Ann Arbor and run in the new 6th district, which was drawn to contain Washtenaw County and Detroit suburbs in western Wayne County. This allowed Rashida Tlaib, who represented the old 13th district, to run in the new 12th district. Dingell faced no opposition in the Democratic primary. In the general election, she defeated Republican Whittney Williams with 65.9% of the vote.
=== 2010s === In January 2010, Sonic announced that they would begin switching to battery cage-free eggs, gestation crate-free pork, and chickens killed using controlled-atmosphere stunning methods instead of traditional shackling and electrical stunning. The company has subsequently backtracked on these commitments and now faces public criticism. Sonic reformulated its soft-serve ice cream to meet the FDA standards of identity that define what constitutes real ice cream and introduced Real Ice Cream on May 17, 2010. Several new hot dog items were also introduced in June 2010 and February 2011. Craig Miller was hired as chief information officer in January 2012. In June 2010, Danielle Vona was hired as chief marketing officer. In late 2010, Sonic announced the end of its 17-year relationship with advertising agency Barkley. A group of specialized agencies was selected to represent the company, and in early 2011, San Francisco-based Goodby Silverstein and Partners was named as the new creative agency for the company. In 2017, Sonic announced it would add seven new stores in Hawaii in the near future. However, its first location in the state would not open unilt May 2026 with a single location in Kapolei. In September 2017, Sonic opened its first location in Alaska in Wasilla, and a year later it opened its second Alaska location in Fairbanks. On September 25, 2018, Atlanta-based Inspire Brands, owner of Arby's and Buffalo Wild Wings, announced that it would acquire Sonic for $2.3 billion. The acquisition was completed on December 7, 2018. While he was with the St.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.